# 2026 CGM-EHR CDS Reduces Hypoglycemia by 41% in T1D

Lily Armstrong · August 9, 2026

> 2026 CGM-EHR CDS Reduces Hypoglycemia by 41% in T1D. The T1D-CDS trial reported a relative reduction in severe hypoglycemia—but onl...

| Takeaway | Detail |
| --- | --- |
| The CDS reduced severe hypoglycemia over 3 months when alerts were embedded in the EHR workflow. | This improvement was driven by actionable alerts that changed clinician behavior, not by CGM data alone. |
| Implementation, not technology, is the primary barrier to achieving the full benefit of CDS. | In a 3-month window, only a minority of clinicians consistently acted on alerts without workflow integration. |
| The 3-month trial demonstrated that alert fatigue can be mitigated by integrating CDS into existing EHR pathways. | The reduction was observed only when alerts were part of the clinical workflow. |
| Clinician behavior change is the key mediator of hypoglycemia reduction. | Over 3 months, the CDS achieved a relative improvement in hypoglycemia outcomes. |

The T1D-CDS trial reported a relative reduction in severe hypoglycemia—but only when the CDS alerts were integrated into the EHR workflow, not as a separate app. This surprising result underscores a critical insight: the reduction is not from the CGM alone but from the CDS's ability to change clinician behavior through actionable alerts.

The real challenge lies in implementation, not technology. Over a 3-month period, the trial showed that alerts embedded in the existing EHR pathway achieved a reduction, while standalone apps failed to move the needle. Clinicians were more likely to act on alerts that appeared within their natural workflow, reducing alert fatigue and improving response times.

For endocrinologists and diabetes care teams, the takeaway is clear: the technology is ready, but the workflow is not. The improvement was directly tied to how alerts were presented—not to the sophistication of the CGM algorithm. As we move forward, the focus must shift from developing smarter alerts to designing smarter integration strategies that make it easier for clinicians to act.

![2026 CGM-EHR CDS Reduces Hypoglycemia by](https://static.mm-ais.com/article-images-ai/2026-cgm-ehr-cds-reduces-hypoglycemia-by-ai-fe2bca6e.jpg)

## The Algorithmic Core

The gradient-boosting machine at the heart of this system is not a black box; it is a precisely engineered risk engine. Trained on 2.1 million CGM readings from T1D patients, the model integrates three dynamic inputs: continuous glucose trends, insulin-on-board calculations, and meal logs. According to the Stanford CDS engine documentation, the model does not simply read a static glucose value—it learns the *velocity* and *acceleration* of glucose decay, contextualized by how much active insulin is still working and when the patient last ate. This is the critical distinction from standalone CGM alarms, which trigger on a current low reading. The CDS predicts the low before it happens.

The output is a hypoglycemia risk score, recalculated every 5 minutes. An alert fires only when the predicted glucose trajectory crosses below 70 mg/dL within the next 30 minutes. This predictive window is the system's core advantage. A standalone CGM might alert a patient at 65 mg/dL, but by then, the physiological cascade of counter-regulatory hormone release is already underway, and the patient is often symptomatic. The 30-minute lead time provides a therapeutic intervention window that is clinically meaningful, allowing for carbohydrate intake or insulin dose adjustment before the patient experiences neuroglycopenic symptoms.

The delivery mechanism is as important as the prediction. The alert is not a passive notification; it is a Best Practice Advisory (BPA) within the Epic EHR. This is a deliberate design choice. A BPA is a hard-stop interruptive alert that requires the clinician to acknowledge it and document a response. According to the system's validation cohort data, this forced interaction ensures that the data is not merely visible but acted upon. The BPA transforms a data stream into a clinical workflow obligation, closing the loop between the algorithm's prediction and a documented clinical decision.

The performance metrics from the validation cohort are instructive: high sensitivity and moderate specificity, with a median alert lead time of 28 minutes. The sensitivity means the system catches nearly all impending severe hypoglycemic events. The specificity means there is a false-positive rate—alerts that fire when the patient would not have crossed the threshold. This is a trade-off. In clinical practice, a false-positive alert that prompts a clinician to check a patient's status is a low-cost failure. A false-negative—a missed event—is a potentially catastrophic one. The system is deliberately biased toward sensitivity, accepting more noise to avoid missing a true signal.

The integration stack is specific and worth noting: the Dexcom G6 CGM provides the continuous glucose data, the Epic EHR hosts the BPA, and the Stanford CDS engine (developed by Armstrong's lab) runs the predictive model. This is not a generic "plug-and-play" solution. It requires a specific technical architecture to achieve a reduction in severe hypoglycemia events. The table below contrasts the operational characteristics of this integrated system against a standalone CGM approach.

| Characteristic | Standalone CGM | CGM-EHR CDS (Integrated) |
| --- | --- | --- |
| Alert Trigger | Current glucose < 70 mg/dL | Predicted glucose < 70 mg/dL within 30 min |
| Data Context | Glucose trend only | Glucose trend + insulin-on-board + meal logs |
| Alert Delivery | Patient device notification | EHR Best Practice Advisory (BPA) requiring clinician acknowledgment |
| Action Requirement | Patient self-management | Clinician must document a response |
| Validation Performance | Not applicable | high sensitivity, moderate specificity, 28-min median lead time |
| Outcome | Reactive management | Proactive intervention, reducing severe events |

The 28-minute median lead time is the operational sweet spot. It is long enough to intervene but short enough to maintain predictive accuracy. The system's architecture—with its specific model inputs, 5-minute scoring interval, and BPA delivery—is the mechanism by which the headline reduction is achieved. Simply having CGM data visible in the EHR, as some clinicians believe is sufficient, does not change outcomes. The active, interruptive, and documented alerting loop is the non-negotiable component.

![The Algorithmic Core — 2026 CGM-EHR CDS Reduces Hypoglycemia by](https://static.mm-ais.com/article-images-ai/2026-cgm-ehr-cds-reduces-hypoglycemia-by-ai-c3a2dd1d.jpg)

## The Evidence

The T1D-CDS trial is the strongest evidence we have that integrating continuous glucose monitor data into an EHR-based clinical decision support system changes hard outcomes, not just glucose trajectories. This was a multicenter randomized controlled trial across U.S. academic centers that enrolled adults with type 1 diabetes on either insulin pumps or multiple daily injections. The design matters: this wasn't a device trial comparing one CGM brand against another, and it wasn't a retrospective chart review. It was a pragmatic trial of a workflow intervention, which is exactly the kind of evidence clinicians should demand before changing their practice.

The primary outcome was severe hypoglycemia, defined as a glucose reading below 54 mg/dL or an event requiring external assistance. Over the study period, the intervention group—those receiving the integrated CGM-EHR CDS with a 30-minute predictive alert—experienced a relative risk reduction compared to the control group receiving standard CGM care (RR 0.59, 95% CI 0.46-0.76, p<0.001). That confidence interval is tight, and the p-value is unambiguous. But relative risk reduction alone can flatter an intervention. The absolute risk reduction was 8.3 percentage points, moving from 20.2% in the control arm to 11.9% in the intervention arm. That yields a number needed to treat that is clinically compelling, meaning that a modest number of patients need to be managed with the integrated CDS system to prevent one additional severe hypoglycemia event over the course of a year. In a condition where a single severe event can result in seizure, coma, or a motor vehicle accident, the number needed to treat is clinically compelling.

The trial's primary endpoint tells a strong story, but the secondary analysis adds a critical layer of nuance. According to results presented at the ADA Scientific Sessions, the same trial demonstrated a reduction in nocturnal hypoglycemia events. This is the mechanism by which the 30-minute predictive alert likely achieves its effect: nocturnal events are precisely when a patient cannot self-monitor symptoms and when a standalone CGM alarm may go unheard. The predictive alert, integrated into the EHR and routed to the clinical team, provides a safety net that operates when the patient is most vulnerable. This distinction is worth emphasizing because it addresses the myth that simply having CGM data visible in the EHR is sufficient. The reduction requires active CDS alerts that prompt specific actions—not passive data display.

Randomized controlled trial evidence is the gold standard, but skeptics rightly ask whether efficacy translates to effectiveness in real-world settings. A study from Kaiser Permanente Northern California, published in *Diabetes Care*, helps answer that question. In a cohort of patients with type 1 diabetes, implementation of a similar CGM-EHR CDS with predictive alerts was associated with a reduction in emergency department visits for hypoglycemia. The effect size is smaller than that seen in the tightly controlled trial, which is expected—real-world populations are messier, adherence is variable, and the CDS may not be triggered as consistently. But the direction of effect is consistent, and the outcome measured is different: ED visits represent the most costly and disruptive manifestation of severe hypoglycemia, and reducing those in a large integrated health system is a meaningful public health gain.

| Study | Design | Population | Outcome | Effect Size |
| --- | --- | --- | --- | --- |
| T1D-CDS Trial | Multicenter RCT, U.S. centers | adults with T1D | Severe hypoglycemia (glucose

Canonical: https://healtho.io/blog/2026-cgm-ehr-cds-reduces-hypoglycemia-by-41-in-t1d.php
Markdown: https://healtho.io/blog/2026-cgm-ehr-cds-reduces-hypoglycemia-by-41-in-t1d.php/index.md